On November 5th, Tom Bollenbach (CTO) and Richard McFarland (CRO), addressed a crowd assembled at the 2nd Annual University of Virginia Advanced Biofabrication Symposium, hosted by Dr. George Christ, Dr. Shayn Peirce-Cottler and the University of Virginia's Schools of Engineering and Applied Sciences and Medicine.
Dr. Bollenbach's talk on "Manufacturing the Future of BioFabrication" covered on a variety of topics emphasizing:
- The current state of the art in engineered tissue manufacturing is inadequate if we want to reach large scale production;
- Scale up and commercial manufacturing of engineered tissues is a multidisciplinary challenge;
- The future will integrate closed systems, automation and Quality by Design principles to mitigate risks and drive down costs; and
- ARMI BioFabUSA will look to fund projects that develop manufacturing platforms and processes to catalyze the commercialization of therapeutic platforms and products.
Dr. McFarland's talk, "The Quest for Coordinated Federal Policy and Practice for Tissue Engineering and Regernative Medicine: The Multi-decade Odyssey of MATES", focused on the events and perspectives leading up to the launch of the 2016 Funding Opportunity Announcement and subsequent award of the "Advanced Tissue Biofabrication - Manufacturing Innovation Institute" (now known as BioFabUSA), to the Advanced Regenerative Manufacturing Institute.